Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bone marrow biopsy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    887 result(s) found for: Bone marrow biopsy. Displaying page 9 of 45.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2009-014876-23 Sponsor Protocol Number: EZN-2208-04 Start Date*: 2010-05-20
    Sponsor Name:Enzon Pharmaceuticals, Inc
    Full Title: A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients with Metastatic Colorectal Carcinoma (mCRC)
    Medical condition: mestatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052358 Colorectal cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003752-79 Sponsor Protocol Number: PIONEER Start Date*: 2017-05-24
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    Full Title: Randomised Phase II clinical trial PIONEER- A Pre-operative wIndOw study of letrozole plus PR agonist (Megestrol Acetate) versus letrozole aloNE in post-menopausal patients with ER-positive breast ...
    Medical condition: ER-positive, HER2-negative, invasive primary breast cancer of at least 1 cm size
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-000128-22 Sponsor Protocol Number: FLIRT Start Date*: 2014-11-26
    Sponsor Name:LYSARC
    Full Title: A randomized phase III trial evaluating two strategies of rituximab administration for the treatment of first line/low tumor burden follicular lymphoma (Follicular Lymphoma IV/SC Rituximab Therapy)
    Medical condition: Stage II-IV follicular lymphoma grade 1-3a not previously treated
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-005856-12 Sponsor Protocol Number: 20221 Start Date*: 2022-01-31
    Sponsor Name:Helsinki University Central Hospital
    Full Title: Monoclonal gammopathies of renal significance (MGRS) in Finland
    Medical condition: Rare renal diseases linked to monoclonal gammopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10038359 Renal and urinary disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003715-26 Sponsor Protocol Number: C4221022 Start Date*: 2022-05-10
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600E-MUTANT, MSI-H/DMMR METASTATIC...
    Medical condition: MSI-H/dMMR metastatic colorectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) NO (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) SE (Trial now transitioned) BE (Trial now transitioned) SK (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005990-29 Sponsor Protocol Number: ENGOT-OV64/NSGO-CTU-SOLERO Start Date*: 2021-12-14
    Sponsor Name:Nordic Society of Gynaecological Oncology - Clinical Trial Unit (NSGO-CTU)
    Full Title: An Early Phase Randomized Trial of APX005M in BRCAwt Patients with Recurrent Ovarian Cancer
    Medical condition: Patients with histologically diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer with radiologically or histologically confirmation of relapsed disease, and with known BRCA wi...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    20.1 10022891 - Investigations 10080244 Peritoneal cancer index PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Prematurely Ended) DK (Prematurely Ended) NO (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000175-13 Sponsor Protocol Number: FIL_PanAL10 Start Date*: 2011-04-26
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: A phase II study of oral Panobinostat in adult patients with relapsed/refractory diffuse large B-cell lymphoma after high-dose chemotherapy with autologous stem cell transfusion (ASCT) or in adult...
    Medical condition: Patient has a history of DLBCL according to the WHO classification. with progressive disease after receiving at least CHOP-R or CHOP-R like first line regimen and is not considered eligible for in...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-005081-17 Sponsor Protocol Number: ARV-471-BC-201 Start Date*: 2023-01-20
    Sponsor Name:Arvinas Estrogen Receptor, Inc. (Arvinas)
    Full Title: An Open-Label, Randomized, Non-Comparative Phase 2 Study of ARV-471 or Anastrozole in Post-Menopausal Women With ER+/HER2– Breast Cancer in the Neoadjuvant Setting
    Medical condition: Post-menopausal women with ER+ HER2– breast cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000617-43 Sponsor Protocol Number: CLEE011F2301 Start Date*: 2015-05-27
    Sponsor Name:Novartis Pharma Services AG
    Full Title: MONALEESA-3: A randomized double-blind, placebo-controlled study of ribociclib in combination with fulvestrant for the treatment of men and postmenopausal women with hormone receptor positive, HER2...
    Medical condition: men and postmenopausal women with HR+, HER2-negative advanced (loco regionally recurrent not amenable to curative therapy or metastatic) breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) AT (Completed) ES (Completed) CZ (Completed) DK (Completed) NL (Completed) HU (Completed) BE (Completed) BG (Completed) FR (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004176-62 Sponsor Protocol Number: CLEE011AIT01 Start Date*: 2018-01-10
    Sponsor Name:NOVARTIS FARMA S.P.A.
    Full Title: A phase IIIb, open-label, local, multicenter study of the molecular features of postmenopausal women with hormone receptor-positive (HR+) HER2-negative advanced breast cancer on first-line treatmen...
    Medical condition: Hormone receptor-positive (HR+) HER2-negative advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004839-23 Sponsor Protocol Number: CA-4948-102 Start Date*: 2023-02-09
    Sponsor Name:Curis, Inc
    Full Title: A Phase 1/2a, Open-Label Dose Escalation and Cohort Expansion Study of Orally Administered CA-4948(IRAK4i) as a Monotherapy in patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome a...
    Medical condition: Acute Myelogenous Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10001941 AML LLT
    20.0 100000004864 10068361 MDS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Completed) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-014446-28 Sponsor Protocol Number: JANUS Start Date*: 2009-12-03
    Sponsor Name:UNIVERSITA` CAMPUS BIOMEDICO
    Full Title: A PHASE II TRANSLATIONAL STUDY INVESTIGATING THE BIOLOGICAL EFFECTS OF THE ZOLEDRONIC ACID AS NEOADJUVANT THERAPY ON INVASIVE PROSTATE CANCER
    Medical condition: invasive prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036917 Prostate cancer stage I LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000515-24 Sponsor Protocol Number: RG_17-247 Start Date*: Information not available in EudraCT
    Sponsor Name:University of Birmingham
    Full Title: FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma
    Medical condition: Rhabdomyosarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039022 Rhabdomyosarcoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Trial now transitioned) NO (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) DK (Trial now transitioned) SI (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001363-12 Sponsor Protocol Number: TRIANGLE Start Date*: 2016-03-24
    Sponsor Name:Klinikum der Universität München, Medizinische Klinik und Poliklinik III
    Full Title: autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial
    Medical condition: Generalized mantle cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026805 Mantle cell lymphoma stage IV PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026804 Mantle cell lymphoma stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026803 Mantle cell lymphoma stage II PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) FI (Trial now transitioned) CZ (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) HR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000565-76 Sponsor Protocol Number: MM-121-02-02-10 Start Date*: 2018-04-05
    Sponsor Name:Merrimack Pharmaceuticals, Inc.
    Full Title: SHERBOC: A Double-blind, Placebo-controlled, Phase 2 trial of Seribantumab Plus Fulvestrant in Postmenopausal Women with Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastat...
    Medical condition: Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) BE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003810-38 Sponsor Protocol Number: KCP-8602-801 Start Date*: 2021-12-01
    Sponsor Name:Karyopharm Therapeutics Inc.
    Full Title: Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients with Newly Diagnosed and Relapsed/R...
    Medical condition: High-risk primary refractory MDS patients
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028535 Myelodysplastic syndrome unclassifiable PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028534 Myelodysplastic syndrome NOS LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067096 5q minus myelodysplastic syndrome LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067387 Myelodysplastic syndrome transformation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-021377-36 Sponsor Protocol Number: BO22334 Start Date*: 2010-11-22
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: “Estudio de fase III en dos etapas, abierto, internacional, multicéntrico, aleatorizado y controlado para investigar la farmacocinética, la eficacia y la seguridad de rituximab s.c. conjuntamente c...
    Medical condition: Linfoma Folicular (LF) CD-20 psoitivo grado 1-2, 3a sin tratar previamente Previously untreated, CD20-positive follicular lymphoma (FL) grade 1-2, 3a
    Disease: Version SOC Term Classification Code Term Level
    12.1 10061170 Follicle centre lymphoma, follicular grade I, II, III LLT
    12.1 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) BE (Completed) SK (Completed) IT (Completed) DK (Completed) DE (Completed) FR (Completed) FI (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-001124-19 Sponsor Protocol Number: 04-24 Start Date*: 2013-09-25
    Sponsor Name:Onconova Therapeutics, Inc.
    Full Title: Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients with Myelodysplastic Syndrome with Excess Bl...
    Medical condition: Myelodysplastic Syndrome
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) SE (Completed) DK (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002620-36 Sponsor Protocol Number: 17000139BLC3001 Start Date*: 2021-05-21
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma...
    Medical condition: Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046714 Urothelial carcinoma bladder LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046720 Urothelial carcinoma bladder stage II LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046721 Urothelial carcinoma bladder stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046722 Urothelial carcinoma bladder stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) PT (Trial now transitioned) AT (Trial now transitioned) PL (Completed) BE (Trial now transitioned) HU (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002272-88 Sponsor Protocol Number: 54767414MMY3007 Start Date*: 2014-10-20
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated...
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) ES (Completed) CZ (Completed) IT (Completed) DE (Completed) BG (Completed) RO (Ongoing) PL (Completed) HR (Completed) GR (Completed) PT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 13:21:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA